Endocyte is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana,[1] a resident of the Purdue Research Park.
[1] The original president and CEO, Ron Ellis,[1] was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016.
SMDCs), which consist of a small molecule linked to a potent drug, and is developing a pipeline of SMDCs together with non-invasive companion imaging agents for cancer, inflammatory diseases and kidney disease (autosomal-dominant polycystic kidney disease/ADPKDor PKD).
[1][5] Endocyte’s lead drug candidate is vintafolide, an investigational targeted cancer therapeutic in late-stage development.
[8] In mid-October 2018, Novartis announced it would acquire Endocyte Inc for $2.1 billion ($24 per share) merging it with a newly created subsidiary.